These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis. Mirsaeidi M; Baughman RP; Sahoo D; Tarau E Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607 [TBL] [Abstract][Full Text] [Related]
5. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review. Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent. Agarwal A; Hassan M; Sepah YJ; Do DV; Nguyen QD Am J Ophthalmol Case Rep; 2016 Dec; 4():78-82. PubMed ID: 29503933 [TBL] [Abstract][Full Text] [Related]
7. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease. Toyos M; Toyos R; Jodoin B; Bunch R Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497 [TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion. Ryder SJ; Iannetta D; Bhaleeya SD; Kiss S Clin Ophthalmol; 2015; 9():1109-16. PubMed ID: 26150689 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Steroidogenic Exposure Following the Administration of Repository Corticotropin Injection With a Synthetic ACTH Wang X; Pham L; Poola N; Brooks LR; Due B Clin Pharmacol Drug Dev; 2021 Jul; 10(7):777-788. PubMed ID: 33369276 [TBL] [Abstract][Full Text] [Related]
11. Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation. Naseer MS; Singh A; Singh N Glomerular Dis; 2022 Apr; 2(2):100-105. PubMed ID: 36751532 [TBL] [Abstract][Full Text] [Related]
12. Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis. Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio MP; Wan GJ J Health Econ Outcomes Res; 2022; 9(1):90-100. PubMed ID: 35529249 [No Abstract] [Full Text] [Related]
13. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Front Neurol; 2020; 11():598496. PubMed ID: 33414758 [No Abstract] [Full Text] [Related]
14. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075 [TBL] [Abstract][Full Text] [Related]
15. Change in visual acuity and retinal structures following Repository Corticotropin Injection (RCI) therapy in patients with acute demyelinating optic neuritis: Improvement in low contrast visual acuity in both affected and contralateral eyes in a single-armed open-label study. Scannell Bryan M; Sergott RC J Neurol Sci; 2019 Dec; 407():116505. PubMed ID: 31706456 [TBL] [Abstract][Full Text] [Related]
16. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Bae JH; Lee SC Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204 [TBL] [Abstract][Full Text] [Related]
17. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Haug SJ; Hien DL; Uludag G; Ngoc TTT; Lajevardi S; Halim MS; Sepah YJ; Do DV; Khanani AM Am J Ophthalmol Case Rep; 2020 Jun; 18():100680. PubMed ID: 32258827 [TBL] [Abstract][Full Text] [Related]
18. Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series. Murray S; Woo A Ther Adv Neurol Disord; 2016 May; 9(3):189-97. PubMed ID: 27134674 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of Repository Corticotropin Gel for Ocular Sarcoidosis. Oh DJ; Singh A; Kanu LN; Lobo-Chan AM; MacIntosh PW; Bhat P Ocul Immunol Inflamm; 2022 Aug; 30(6):1420-1424. PubMed ID: 33826473 [TBL] [Abstract][Full Text] [Related]
20. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States. Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]